Clinical Trial Update: An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) [Phase 4]

View source ↗

Summary

Phase 4 open-label expanded access study of everolimus in advanced neuroendocrine tumors completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neuroendocrine Tumors | Phase 4 | Status: COMPLETED | Results posted: 2018-11-29